Collaborative Practice in the Management of Patients with Gastrointestinal and Pancreatic Neuroendocrine Tumors

November 7, 2015

Learning Objectives

  • Discuss how medical therapies fit within the wider range of treatment options available to patients with gastrointestinal or pancreatic neuroendocrine tumors
  • Define the role of mTOR inhibitors and tyrosine kinase inhibitors in patients with recurrent disease
  • Review the role of somatostatin analogs in patients with both functional and nonfunctional tumors
  • Describe best practices for preventing choloecystitis and other adverse reactions associated with medical therapy for pNETs
  • Recall key laboratory and imaging studies recommended for patients being trated for pNETs
Course summary
Available credit: 
  • 1.00 AANP
  • 0.67 Pharmacology
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC
Course opens: 
11/07/2015
Course expires: 
02/29/2016
Event starts: 
11/07/2015 - 1:30pm
Event ends: 
11/07/2015 - 2:30pm
Cost:
$0.00
Parent activity set: 
Concurrent Sessions 1:30-2:30PM
Add to calendar: 
Rating: 
0
United States

Jennifer Ang Chan, MD, MPH
Robin Sommers, NP

Available Credit

  • 1.00 AANP
  • 0.67 Pharmacology
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC

Price

Cost:
$0.00
Please login or register to take this course.